UK becomes first in Europe to approve new once-daily weight loss pill

1 sources1 storiesFirst seen 8/10/2026Score19Breakthrough

Single Source

Bigness

Coverage

Recency

Engagement

Velocity

Confidence

Clipability

Polarization

Claims

Contradictions

Breakthrough

100

Sentiment Mix

Positive0%

Neutral100%

Negative0%

Geography

EuropeNorth America

Expert Signals

GB News - News

source • 1 mention

AI-Generated Claims

Generated from linked receipts; click sources for full context.

Britain's medicines regulator has today granted approval to orforglipron, marketed under the brand name Foundayo, positioning the UK as the first nation in Europe to greenlight this oral GLP-1 treatment for weight management and type 2 diabetes.The Medicines and Healthcare products Regulatory Agency confirmed the authorisation on Monday, marking a significant milestone for patients seeking alternatives to injectable weight-loss therapies.The once-daily tablet has been cleared for use by adults living with obesity, defined as a body mass index of 30 or greater, as well as those with a BMI between 27 and 30 who also have at least one weight-related health condition.The drug is intended to complement a reduced-calorie diet and greater physical activity, and is also approved for improving blood sugar control in adults whose type 2 diabetes remains insufficiently managed.

Supported by 1 story

TRENDING Stories Videos Your Say Dosing starts at 0.8 mg, rising incrementally through six levels up to a maximum of...

Supported by 1 story